SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES

被引：0
|
作者：
Sartor, O. [1 ,2 ]
Coleman, R. E. [3 ]
Nilsson, S. [4 ]
Vogelzang, N. [5 ]
Cross, A. [6 ]
O'Bryan-Tear, G. [7 ]
Staudacher, K. [7 ]
Garcia-Vargas, J. E. [8 ]
Zou, J. [9 ]
Parker, C. [10 ]
机构：
[1] Tulane Canc Ctr, Sect Hematol & Med Oncol, Dept Med, New Orleans, LA USA
[2] Tulane Canc Ctr, Dept Urol, New Orleans, LA USA
[3] Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England
[4] Karolinska Univ Hosp, Radiumhemmet, Stockholm, Sweden
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[6] PharmaNet, Biostat, Hemel, Hempstead, England
[7] Algeta ASA, Oslo, Norway
[8] Bayer HealthCare Pharmaceut, Oncol Global Clin Programs, Montville, NJ USA
[9] Bayer HealthCare Pharmaceut, Global Med Affairs, Montville, NJ USA
[10] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：308 / 309
页数：2
相关论文
共 50 条
  • [21] Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Parker, C.
    Heinrich, D.
    Bottomley, D.
    Hoskin, P.
    Franzen, L.
    Solberg, A.
    Pawar, V.
    Reuning-Scherer, J.
    O'Bryan-Tear, C. G.
    Nilsson, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S689 - S689
  • [22] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
    Finkelstein, S. E.
    Michalski, J. M.
    O'Sullivan, J.
    Parker, C.
    Garcia-Vargas, J.
    Sartor, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
  • [23] 1.5-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study
    Kuczyk, M.
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Bottomley, D.
    Coleman, R.
    Skjorestad, I.
    Whaba, M.
    Nilsson, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 178 - 178
  • [24] 3-year safety follow-up of Radium-223 Dichloride (Ra-223) in patients (Pts) with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Kramer, M. W.
    Kuczyk, M. A.
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Coleman, R. E.
    Fang, F.
    Skjorestad, I
    Nilsson, S.
    Oncology Research and Treatment, 2015, 38 : 266 - 266
  • [25] Radium-223 dichloride (Ra-223) hematologic and 1.5-year posttreatment safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from ALSYMPCA
    Conti, Peter
    Michalski, Jeff
    Skjorestad, Irene
    Wahba, Mona
    Nilsson, Sten
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [26] Radium-223(Ra-223) safety and efficacy in prostate cancer with bone metastases: phase 3 ALSYMPCA study findings stratified by age
    Sartor, Oliver
    Coleman, Robert
    Nilsson, Sten
    Heinrich, Daniel
    Staudacher, Karin
    Garcia-Vargas, Jose
    Vogelzang, Nicholas
    BJU INTERNATIONAL, 2013, 112 : 15 - 16
  • [27] 3-year safety yellow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Parker, Chris
    Vogelzang, Nicholas J.
    Salter, A. Oliver
    Coleman, Robert E.
    Fang, Fang
    Skjorestad, Irene
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [28] Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM): A multicenter analysis.
    Omlin, Aurelius Gabriel
    Daugaard, Gedske
    Peer, Avivit
    Reichegger, Hermann
    Neumann, Avivit
    Rosenbaum, Eli
    Desax, Marie-Claire
    Neiman, Victoria
    Petersen, Peter Meidahl
    Mueller, Joachim
    Cathomas, Richard
    Gottfried, Maya
    Sarid, David
    Gez, Eli
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Mortensen, Jann
    Gillessen, Silke
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Updated Analysis of Radium-223 Dichloride (Ra-223) Impact on Survival, Safety, and Skeletal-Related Events in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases From the Phase 3 ALSYMPCA Trial
    Wedel, S.
    Kranert, T. W.
    Chodacki, A.
    Staudacher, K.
    Garcia-Vargas, J.
    Parker, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S190 - S190
  • [30] UPDATED SURVIVAL, QUALITY OF LIFE (QOL), AND SAFETY DATA OF RADIUM-223 CHLORIDE (RA-223) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES FROM THE PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTINATIONAL STUDY (ALSYMPCA)
    Parker, C.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Lloyd, A. J.
    Staudacher, K.
    van Gool, R.
    Sartor, A. O.
    ANNALS OF ONCOLOGY, 2012, 23 : 296 - 296
12345